Topical analgesics for neuropathic pain: Preclinical exploration, clinical validation, future development

European Journal of Pain (United Kingdom)

Volumn 18, Issue 4, 2014, Pages 465-481

  Sawynok, J ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR; ALPHA ADRENERGIC RECEPTOR; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; CANNABINOID; CAPSAICIN; GLUTAMATE RECEPTOR; LIDOCAINE; NEW DRUG; OPIATE; SODIUM CHANNEL BLOCKING AGENT; TRANSIENT RECEPTOR POTENTIAL CHANNEL; VASODILATOR AGENT;

ANALGESIA; CLINICAL FEATURE; CLINICAL STUDY; DRUG MECHANISM; DRUG RESPONSE; DRUG SCREENING; EPIDERMAL NERVE FIBER; HUMAN; LOCAL THERAPY; META ANALYSIS (TOPIC); NERVE CELL PLASTICITY; NERVE FIBER; NERVOUS TISSUE; NEUROPATHIC PAIN; PAIN ASSESSMENT; PATHOGENESIS; PERIPHERAL NERVE; PERIPHERAL TISSUE PLASTICITY; POST HOC ANALYSIS; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY SYSTEM EXAMINATION; SYSTEMATIC REVIEW (TOPIC); VALIDATION STUDY;

ADMINISTRATION, TOPICAL; ANALGESICS; CLINICAL TRIALS AS TOPIC; HUMANS; NEURALGIA; NEURONAL PLASTICITY; PAIN MANAGEMENT;

EID: 84898837846     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1002/j.1532-2149.2013.00400.x     Document Type: Review

References (171)

1. Agarwal, N., Pacher, P., Tegeder, I., Amaya, F., Constantin, C.E., Brenner, G.J., Rubino, T., Michalski, C.W., Marsicano, G., Monory, K., Mackie, K., Marian, C., Batkai, S., Parolaro, D., Fisher, M.J., Reeh, P., Kunos, G., Kress, M., Lutz, B., Woolf, C.J., Kuner, R., (2007). Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10, 870-879.
2. Albrecht, P.J., Rice, F.L., (2010). Role of small-fibre afferents in pain mechanisms with implications on diagnosis and treatment. Curr Pain Headache Rep 14, 179-188.
3. Amos, K., Yeoh, S.C., Farah, C.S., (2011). Combined topical and systemic clonazepam therapy for the management of burning mouth syndrome: A retrospective pilot study. J Orofac Pain 25, 125-130.
4. Anand, P., Bley, K., (2011). Topical capsaicin for pain management: Therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anesth 107, 490-502.
5. Anand, P., Whiteside, G., Fowler, C.J., Hohmann, A.G., (2009). Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev 60, 255-266.
6. Anand, U., Otto, W.R., Sanchez-Herrera, D., Facer, P., Yiangou, Y., Korchev, Y., Birch, R., Benham, C., Bountra, C., Chessell, I.P., Anand, P., (2008). Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain 138, 667-680.
7. Argoff, C.E., (2013). Topical analgesics in the management of acute and chronic pain. Mayo Clin Proc 88, 195-205.
8. Attal, N., Baron, R., Haanpää, M., Hansson, P., Jensen, T.S., (2010). EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 17, 1113-1123.
9. Backonja, M., Wallace, M.S., Blonsky, E.R., Cutler, B.J., Malan, P., Rauch, R., Tobias, J.K., (2008). NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: A randomized, double-blind study. Lancet Neurol 7, 1106-1112.
10. Backonja, M.M., Irving, G., Argoff, C., (2006). Rational multidrug therapy in the treatment of neuropathic pain. Curr Pain Headache Rep 10, 34-38.
11. Backonja, M.M., Malan, T.P., Vanhove, G.F., Tobias, J.K., (2010). NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuraglia: A randomized, double-blind, controlled study with an open-label extension. Pain Med 11, 600-608.
12. Baron, R., (2010). Neuropathic pain: Diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 9, 807-819.
13. Baron, R., Levine, J.D., Fields, H.L., (1999). Causalgia and reflex sympathetic dystrophy: Does the sympathetic nervous system contribute to the generation of pain ? Muscle Nerve 22, 678-695.
14. Baron, R., Mayoral, V., Leijon, G., Binder, A., Steigerwald, I., Serpell, M., (2009a). 5% Lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: An open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 25, 1663-1676.
15. Baron, R., Mayoral, V., Leijon, G., Binder, A., Steigerwald, I., Serpell, M., (2009b). Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic neuropathy. Curr Med Res Opin 25, 1677-1687.
16. Barton, D.L., Wos, E.J., Qin, R., Mattar, B.I., Green, N.B., Lanier, K.S., Bearden, J.D., Kugler, J.W., Hoff, K.L., Reddy, P.S., Rowland, K.M., Riepel, M., Christensen, B., Loprinzi, C.L., (2011). A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: CCCTG trial N06CA. Support Care Cancer 19, 833-841.
17. Bennett, M.I., Smith, B.H., Torrance, N., Lee, A.J., (2006). Can pain be more or less neuropathic? Comparison of symptom assessment tools with ratings of certainty by clinicians. Pain 122, 289-294.
18. Bernstein, L.R., (2012). Successful treatment of refractory postherpetic neuralgia with topical gallium maltolate: Case report. Pain Med 13, 915-918.
19. Binder, A., Bruxelle, J., Rogers, P., Hans, G., Bösl, I., Baron, R., (2009). Topical 5% lidocaine (lignocaine) medicated plaster for post-herpetic neuralgia. Clin Drug Investig 29, 393-408.
20. Boardman, L.A., Cooper, A.S., Blais, L.R., Raker, C.A., (2008). Topical gabapentin in the treatment of localized and generalized vulvodynia. Obstet Gynecol 112, 579-585.
21. Boulais, N., Misery, L., (2008). The epidermis: A sensory tissue. Eur J Dermatol 18, 119-127.
22. Byas-Smith, M., Max, M.B., Muir, J., Kingman, A., (1995). Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design. Pain 60, 267-274.
23. Cairns, B.E., ed. (2009). Peripheral Receptor Targets for Analgesia. Novel Approaches to Pain Management (New Jersey: Wiley).
24. Campbell, C.M., Kipnes, M.S., Stouch, B.C., Brady, K.L., Kelly, M., Schmidt, W.K., Peterson, K.L., Rowbotham, M.C., Campbell, J.N., (2012). Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain 153, 1815-1823.
25. Cassuto, J., Sinclair, R., Bonderovic, M., (2006). Anti-inflammatory properties of local anesthetics and their present and potential clinical implications. Acta Anesthesiol Scand 50, 265-282.
26. Chiu, I.M., von Hehn, C.A., Woolf, C.J., (2012). Neurogenic inflammation and the peripheral nervous system in host defence and immunopathology. Nat Neurosci 15, 1063-1067.
27. Chung, C., Carteret, A.F., McKelcy, A.D., Ringkamp, M., Yang, F., Hartke, T.V., Dong, X., Raja, S.N., Guan, Y., (2012). Analgesic properties of loperamide differ following systemic and local administration to rats after spinal nerve injury. Eur J Pain 16, 1021-1032.
28. Coderre, T.J., Bennett, G.J., (2010). A hypothesis for the cause of complex regional pain syndrome-type 1 (reflex sympathetic dystrophy): pain due to deep-tissue microvascular pathology. Pain Med 11, 1224-1238.
29. Costigan, M., Scholz, J., Woolf, C.J., (2009). Neuropathic pain: A maladaptive response of the nervous system to damage. Annu Rev Neurosci 32, 1-32.
30. Davis, K.D., Treede, R.D., Raja, S.N., Meyer, R.A., Campbell, J.N., (1991). Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. Pain 47, 309-317.
31. Davis, P.S., Galer, B.S., (2004). Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 64, 937-947.
32. Derry, S., Lloyd, R., Moore, R.A., McQuay, H.J., (2009). Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 4, CD007393.
33. Derry, S., Moore, R.A., (2012). Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 9, CD010111.
34. Derry, S., Sven-Rice, A., Cole, P., Tan, T., Moore, R.A., (2013). Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2, CD007393.
35. Dib-Hajj, S.D., Cummins, T.R., Black, J.A., Waxman, S.G., (2009). Voltage-gated sodium channels: Therapeutic targets for pain. Pain Med 10, 1260-1269.
36. Dib-Hajj, S.D., Cummins, T.R., Black, J.A., Waxman, S.G., (2010). Sodium channels in normal and pathological pain. Annu Rev Neurosci 33, 325-347.
37. Dussor, G., Koerber, H.R., Oaklander, A.L., Rice, F.L., Molliver, D.C., (2009). Nucleotide signaling and cutaneous mechanisms of pain transduction. Brain Res Rev 60, 24-35.
38. Dworkin, R.H., O'Conner, A.B., Audette, J., Baron, R., Gourlay, C.K., Haanpää, M.L., Kent, J.L., Krane, E.J., LeBel, A.A., Levy, R.M., Mackey, S.C., Mayer, J., Miaskowski, C., Raja, S.N., Rice, A.S.C., Schmader, K.E., Stacey, B., Santos, S., Treede, R.D., Turk, D.C., Walco, G.A., Wells, C.D., (2010). Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc 85, S3-S14.
39. Ebenezer, G.J., Hauer, P., Gibbons, C., McArthur, J.C., Polydefkis, M., (2007). Assessment of epidermal nerve fibres: A new diagnostic and predictive tool for peripheral neuropathies. J Neuropathol Exp Neurol 66, 1059-1073.
40. Epstein, J.B., Epstein, J.D., Epstein, M.S., Oien, H., Truelove, E.L., (2006). Oral doxepin rinse: The analgesic effect and duration of pain reduction in patients with oral mucositis due to cancer therapy. Anesth Analg 103, 465-470.
41. Epstein, J.B., Epstein, J.D., Epstein, M.S., Oien, H., Truelove, E.L., (2008). Doxepin rinse for management of mucositis pain in patients with cancer: One week follow-up of topical therapy. Spec Care Dentist 28, 73-77.
42. Epstein, J.B., Grushka, M., Le, N., (1997). Topical clonidine for orofacial pain: A pilot study. J Orofac Pain 11, 346-351.
43. Esser, M.J., Sawynok, J., (1999). Acute amitriptyline in a rat model of neuropathic pain: Differential symptom and route effects. Pain 80, 643-653.
44. Finch, P.M., Knudsen, L., Drummond, P.D., (2009). Reduction of allodynia in patients with complex regional pain syndrome; a double-blind placebo-controlled trial of topical ketamine. Pain 146, 18-25.
45. Finnerup, N.B., Sindrup, S.H., Jensen, T.S., (2010). The evidence for pharmacological treatment of neuropathic pain. Pain 150, 573-581.
46. Gammaitoni, A.R., Alvarez, N.A., Galer, B.S., (2003). Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: A review of the literature. J Clin Pharmacol 43, 111-117.
47. Garnock-Jones, K.P., Keating, G.M., (2009). Lidocaine 5% medicated plaster. A review of its use in postherpetic neuralgia. Drugs 69, 2149-2165.
48. Geha, P.Y., Baliki, M.N., Chialvo, D.R., Harden, R.N., Paice, J.A., Apkaparian, A.V., (2007). Brain activity for spontaneous pain of postherpetic neuralgia and its modulation by lidocaine patch therapy. Pain 128, 88-100.
49. Gerner, P., (2004). Tricyclic antidepressants and their local anesthetic properties: From bench to bedside and back again. Reg Anesth Pain Med 29, 286-289.
50. Gerner, P., Kao, G., Srinivasa, V., Narang, S., Wang, G.K., (2003). Topical amitriptyline in healthy volunteers. Reg Anesth Pain Med 28, 289-293.
51. Gibbs, G.F., Drummond, P.D., Finch, P.M., Phillips, J.K., (2008). Unravelling the pathophysiology of complex regional pain syndrome: Focus on sympathetically maintained pain. Clin Exp Pharmacol Physiol 35, 717-724.
52. Gilron, I., Wajsbrot, D., Therrien, F., Lemay, J., (2011). Pregabalin for peripheral neuropathic pain: A multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. Clin J Pain 27, 185-193.
53. + channel blockers for the treatment of pain: Context is everything, almost. Exp Neurol 210, 1-6.
54. Gold, M.S., Gebhart, G.F., (2010). Nociceptor sensitization in pain pathogenesis. Nat Med 16, 1248-1257.
55. 1 receptors mediate local anti-nociceptive effects of acupuncture. Nat Neurosci 13, 883-889.
56. Gottrup, H.M., Bach, F.W., Jensen, T.S., (2004). Differential effects of peripheral ketamine and lidocaine on skin flux and hyperalgesia induced by intradermal capsaicin in humans. Clin Physiol Funct Imaging 24, 103-108.
57. Goudet, C., Magnaghi, V., Landry, M., Nagy, F., Gereau, R.W., Pin, J.P., (2009). Metabotropic receptors for glutamate and GABA in pain. Brain Res Rev 60, 43-56.
58. Gremeau-Richard, C., Woda, A., Navez, M.L., Attal, N., Bouhassira, D., Gagnieu, M.C., Laluque, J.F., Picard, P., Pionchon, P., Tubert, S., (2004). Topical clonazepam in stomatodynia: A randomised placebo-controlled study. Pain 108, 51-57.
59. Guan, Y., Johanek, L.M., Hartke, T.V., Shim, B., Tao, Y.X., Ringkamp, M., Meyer, R.A., Raja, S.N., (2008). Peripherally acting mu-opioid receptor agonist attenuates neuropathic pain in rats after L5 spinal nerve injury. Pain 138, 318-329.
60. Guindon, J., Hohmann, A.G., (2008). Cannabinoid CB2 receptors: A therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153, 319-334.
61. Gutierrez, T., Farthing, J.N., Zvonok, A.M., Makriyannis, A., Hohmann, A.G., (2007). Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: A comparative analysis. Br J Pharmacol 150, 153-163.
62. Haanpää, M., Treede, R.D., (2012). Capsaicin for neuropathic pain: Linking traditional medicine and molecular biology. Eur J Neurol 68, 264-275.
63. Haribabu, P.K., Eliav, E., Heir, G.M., (2013). Topical medications for the effective management of neuropathic orofacial pain. JADA 144, 612-614.
64. Hashmi, J.A., Baliki, M.N., Huang, L., Parks, E.L., Chanda, M.L., Schnitzer, T., Apkarian, A.V., (2012). Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study. Mol Pain 8, 29.
65. Heir, G., Karolchek, S., Kalladka, M., Vishwanath, A., Gomes, J., Khatri, R., Nasri, C., Eliav, E., Ananthan, S., (2008). Use of topical medication in orofacial neuropathic pain: A retrospective study. Surg Oral Med Oral Pathol Oral Radiol Endod 105, 466-469.
66. Herrmann, D.N., Pannoni, V., Barbano, R.L., Penjnella-Vaughan, J., Dworkin, R.H., (2006). Skin biopsy and quantitative sensory testing do not predict response to lidocaine patch in painful neuropathies. Muscle Nerve 33, 42-48.
67. Hou, Q., Barr, T., Gee, L., Vickers, J., Wymer, J., Borsani, E., Rodella, L., Getsios, S., Burdo, T., Eisenberg, E., Guha, U., Lavker, R., Kessler, J., Chittur, S., Fiorino, D., Rice, F., Albrecht, P., (2011). Keratinocyte expression of calcitonin gene-related peptide β: implications for neuropathic and inflammatory pain mechanism. Pain 152, 2036-2051.
68. 2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol 162, 428-440.
69. Hurt, J.K., Zylka, M.J., (2012). PAPupuncture has localized and long-lasting antinociceptive effects in mouse models of acute and chronic pain. Mol Pain 8, 28.
70. 2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 102, 3093-3098.
71. Irving, G.A., Backonja, M., Rauck, R., Webster, L.R., Tobias, J.K., Vanhove, G.F., (2012). NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Clin J Pain 28, 101-107.
72. Jaggi, A.S., Jain, V., Singh, N., (2011). Animal models of neuropathic pain. Fundam Clin Pharmacol 25, 1-28.
73. Jensen, T.S., Baron, R., Haanpää, M., Kalso, E., Loeser, J.D., Rice, A.S.C., Treede, R.D., (2011). A new definition of neuropathic pain. Pain 152, 2204-2205.
74. Kalso, E., Smith, L., McQuay, H.J., Moore, R.A., (2002). No pain, no gain: Clinical excellence and scientific rigour-lessons learned from IA morphine. Pain 98, 269-275.
75. Kanai, A., Okamoto, T., Suzuki, K., Niki, Y., Okamoto, H., (2010). Lidocaine eye drops attenuate pain associated with ophthalmic postherpetic neuralgia. Anesth Analg 110, 1457-1460.
76. Katz, N., (2009). Enriched enrollment randomized withdrawal trial designs for analgesics. Focus on methodology. Clin J Pain 25, 797-807.
77. Kennedy, W.R., Vanhove, G., Shiao-Ping, L., Tobias, J., Bley, K.R., Walk, D., Wendelschafer-Crabb, G., Simone, D.A., Selim, M.M., (2010). A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain 11, 579-587.
78. Kern, K.U., Nalamachu, S., Brasseru, L., Zakrzewsks, J.M., (2013). Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain. J Pain Res 6, 261-280.
79. Kharkar, S., Venkatesh, Y.S., Grothusen, J.R., Rojas, L., Schwartzman, R.J., (2012). Skin biopsy in complex regional pain syndrome: Case series and literature review. Pain Physician 15, 255-266.
80. Kopsky, D.J., Amelink, G.J., Keppel Hesselink, J.M., (2012a). Intractable neuropathic pain in spinal intramedullary cavernoma treated successfully with a novel combination cream. Pain Med 13, 729-730.
81. Kopsky, D.J., Keppel Hesselink, J.M., (2012). High doses of topical amitriptyline in neuropathic pain: Two cases and literature review. Pain Pract 12, 148-153.
82. Kopsky, D.J., Liebregts, R., Keppel Hesselink, J.M., (2012b). Central neuropathic pain in a patient with multiple sclerosis treated successfully with topical amitriptyline. Case Report Med Article ID 471835.
83. Krumova, E.K., Zeller, M., Westermann, A., Maier, C., (2012). Lidocaine patch (5%) induces only partial blockade of Aδ- and C-fibres to variable extent. Pain 153, 273-280.
84. Kulkantrakorn, K., Lorsumansiri, C., Meesawatsom, P., (2012). 0.025% Capsaicin gel for the treatment of painful diabetic neuropathy: A randomized, double-blind, crossover, placebo-controlled trial. Pain Pract 13, 497-503.
85. Lam, V.Y., Wallace, M., Schulteis, G., (2011). Effects of lidocaine patch on intradermal capsaicin-induced pain: A double-blind, controlled trial. J Pain 12, 323-330.
86. LeBon, B., Zeppetella, G., Higginson, I.J., (2009). Effectiveness of topical administration of opioids in palliative care: A systematic review. J Pain Symptom Manage 37, 913-917.
87. Leffler, A., Fisher, M.J., Rehner, D., Kienel, S., Kistner, K., Sauer, S.K., Gaava, N.R., Reeh, P.W., Nau, C., (2008). The vanilloid receptor TRPV1 is activated and sensitized by local anesthetics in rodent sensory neurons. J Clin Invest 118, 763-776.
88. Leffler, A., Lattrel, A., Kronewald, S., Niedermirtl, F., Nau, C., (2011). Activation of TRPA1 by membrane permeable local anesthetics. Mol Pain 7, 62.
89. Lehman, J.S., Sciallis, G.F., (2008). Effective use of topical amitriptyline hydrochloride 2.5% and ketamine hydrochloride 0.5% for analgesia in refractory proctodynia. J Drugs Dermatol 7, 887-889.
90. Li, C., Sekiyama, H., Hayashida, M., Takeda, K., Sumida, T., Sawamura, S., Yamada, Y., Arita, H., Hanaoka, K., (2007). Effects of topical application of clonidine cream on pain behaviors and spinal Fos protein expression in rat models of neuropathic pain, postoperative pain, and inflammatory pain. Anesthesiology 107, 486-494.
91. Lima, F.O., Souza, G.R., Verri, W.A., Parada, C.A., Ferreira, S.H., Cunha, F.Q., Cunha, T.M., (2010). Direct blockade of inflammatory hypernociception by peripheral A1 adenosine receptors: Involvement of the NO/cGMP/PKG/KATP signaling pathway. Pain 151, 506-515.
92. Lumpkin, E.A., Caterina, M.J., (2007). Mechanisms of sensory transduction in the skin. Nature 445, 858-865.
93. Lutwak, N., Howland, M.A., Gambetta, R., Dill, C., (2013). Even 'safe' medications need to be administered with care. BMJ Case Rep. doi: 10.1136/bcr2012006204.
94. Malmberg, A.B., Mizisin, A.P., Calcutt, N.A., von Stein, T., Robbins, W.E., Bley, K.R., (2004). Reduced heat sensitivity and epidermal nerve fiber immunostaining following single applications of a high-concentration capsaicin patch. Pain 111, 360-367.
95. Mankovsky, T., Lynch, M.E., Clark, A.J., Sawynok, J., Sullivan, M.J.L., (2012). Pain catastrophizing predicts poor response to topical analgesics in patients with neuropathic pain. Pain Res Manage 17, 10-14.
96. Martini, C., Yassen, A., Olofsen, E., Passier, P., Stoker, M., Dahan, A., (2012). Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza™) in diabetic neuropathy pain patients: Detection of distinct response groups. J Pain Res 5, 51-59.
97. Martins, D.F., Mazzardo-Martins, L., Soldi, F., Stramosk, J., Piovezan, A.P., Santos, A.R.S., (2013). High-intensity swimming exercise reduces neuropathic pain in an animal model of complex regional pain syndrome type 1: evidence for a role of the adenosinergic system. Neuroscience 234C, 67-76.
98. McCormack, P.L., (2010). Capsaicin dermal patch in non-diabetic peripheral neuropathic pain. Drugs 70, 1831-1842.
99. McMahon, S.B., Malcangio, M., (2009). Current challenges in glia-pain biology. Neuron 64, 46-54.
100. Mick, G., Baron, R., Finnerup, N.B., Hans, G., Kern, K.U., Brett, B., Dworkin, R.H., (2012). What is localized neuropathic pain? A first proposal to characterize and define a widely used term. Pain Manage 2, 71-77.
101. Mick, G., Correa-Illanes, G., (2012). Topical pain management with the 5% lidocaine medicated plaster-a review. Curr Med Res Opin 28, 937-951.
102. Micõ, J.A., Ardid, D., Berrocoso, E., Eschalier, A., (2006). Antidepressants and pain. Trends Pharmacol Sci 27, 349-354.
103. Miller, K.E., Hoffman, E.M., Sutharshan, M., Schechter, R., (2011). Glutamate pharmacology and metabolism in peripheral primary afferents: Physiological and pathophysiological mechanisms. Pharmacol Ther 130, 283-309.
104. Milligan, E.D., Watkins, L.R., (2009). Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 10, 23-36.
105. Moghadamnia, A.A., Partovi, M., Mohammadianfar, I., Madani, Z., Zabihi, E., Hamidi, M.R., Baradaran, M., (2009). Evaluation of the effect of locally administered amitriptyline gel as adjunct to local anesthetics in irreversible pulpitis pain. Indian J Den Res 20, 3-6.
106. Nicolaou, A., Nicholson, B., Hans, G., Brasseur, L., (2011). Outcome predictors for treatment success with 5% lidocaine medicated plaster in low back pain with neuropathic pain components and neuropathic pain after surgical and nonsurgical trauma. J Pain Res 4, 25-38.
107. Nolano, M., Simone, D.A., Wendelschafer-Crabb, G., Johnson, T., Hazen, E., Kennedy, W.R., (1999). Topical capsaicin in humans: Parallel loss of epidermal nerve fibers and pain sensation. Pain 81, 135-145.
108. Nyirjesy, P., Lev-Sagie, A., Mathew, L., Culhane, J.F., (2009). Topical amitriptyline-baclofen cream for the treatment of provoked vestibulodynia. J Lower Genital Tract Dis 13, 230-236.
109. Obara, I., Parkitna, J.R., Korostynski, M., Makuch, W., Kaminska, D., Przewlocka, B., Przewlocki, R., (2009). Local peripheral opioid effects and expression of opioid genes in the spinal cord and dorsal root ganglia in neuropathic and inflammatory pain. Pain 141, 283-291.
110. Padilla, M., Clark, G.T., Merrill, R.L., (2000). Topical medications for orofacial neuropathic pain: A review. JADA 131, 184-195.
111. Pagano, R., Wong, S.W., (2012). Use of amitriptyline cream in the management of entry dyspareunia due to provoked vestibulodynia. J Lower Genital Tract Dis 16, 394-397.
112. Pedersen, J.L., Galle, T.S., Kehlet, H., (1998). Peripheral analgesic effects of ketamine in acute inflammatory pain. Anesthesiology 89, 58-66.
113. Persson, A.K., Black, J.A., Gasser, A., Cheng, X., Fisher, T.Z., Waxman, S.G., (2010). Sodium-calcium exchanger and multiple sodium channel isoforms in intra-epidermal nerve terminals. Mol Pain 6, 84.
114. Pertovaara, A., (2006). Noradrenergic pain modulation. Prog Neurobiol 80, 53-83.
115. Pertovaara, A., (2009). Adrenergic receptors. In Peripheral Receptor Targets for Analgesia: Novel Approaches to Pain Management, B.E. Cairns, ed. (Hoboken, NJ: Wiley) pp. 275-296.
116. Petersen, K.L., Rice, F.L., Farhadi, M., Reda, H., Rowbotham, M.C., (2010). Natural history of cutaneous innervation following herpes zoster. Pain 150, 75-82.
117. Pezet, S., McMahon, S.B., (2006). Neurotrophins: Mediators and modulators of pain. Annu Rev Neurosci 29, 507-538.
118. Polydefkis, M., Yiannoutsos, C.T., Cohen, B.A., Hollander, H., Schifitto, G., Clifford, D.B., Simpson, D.M., Katzenstein, D., Shriver, S., Hauer, P., Brown, A., Haidich, A.B., Moo, L., McArthur, J.C., (2002). Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy. Neurology 58, 115-119.
119. Poterucha, T.J., Murphy, S.L., Rho, R.H., Sandroni, P., Warndahl, R.A., Weiss, W.T., Davis, M.D.P., (2012). Topical amitriptyline-ketamine for treatment of rectal, genital, and perineal pain and discomfort. Pain Physician 15, 485-488.
120. Pöyhiä, R., Vainio, A., (2006). Topically administered ketamine reduces capsaicin-evoked mechanical hyperalgesia. Clin J Pain 22, 32-36.
121. Premkumar, L.S., Abooj, M., (2013). TRP channels and analgesia. Life Sci 92, 415-424.
122. Radtke, C., Vogt, P.M., Devor, M., Kocsis, J.D., (2010). Keratinocytes acting on injured afferents induce extreme neuronal hyperexcitability and chronic pain. Pain 148, 94-102.
123. Ragavendran, J.V., Laferrière, A., Xiao, W.H., Bennett, G.J., Padi, S.S.V., Zhang, J., Coderre, T.J., (2013). Topical combinations aimed at treating microvascular dysfunction reduce allodynia in rat models of CRPS-1 and neuropathic pain. J Pain 14, 66-78.
124. Rehm, S., Binder, A., Baron, R., (2010). Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr Med Res Opin 26, 1607-1619.
125. Romero-Sandoval, A., Eisenach, J.C., (2007). Clonidine reduces hypersensitivity and alters the balance of pro- and anti-inflammatory leukocytes after local injection at the site of inflammatory neuritis. Brain Behav Immun 21, 569-580.
126. Roosterman, D., Doerge, T., Schneider, S.W., Bunnett, N.W., Steinhoff, M., (2006). Neuronal control of skin function: The skin as a neuroimmunoendocrine organ. Physiol Rev 86, 1309-1379.
127. Rukwied, R., Watkinson, A., McGlone, F., Dvorak, M., (2003). Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 102, 283-288.
128. Sawynok, J., (2013). Adenosine and pain. In Adenosine. A Key Link Between Metabolism and Brain Activity, S. Masino, D. Boison, ed. (New York: Springer) pp. 343-360.
129. Schley, M., Bayram, A., Rukwied, R., Dusch, M., Konrad, C., Benrath, J., Geber, C., Birklein, F., Hägglöf, B., Sjögren, N., Gee, L., Albrecht, P.J., Rice, F.L., Schmelz, M., (2012). Skin innervation at different depths correlates with small fibre function but not with pain in neuropathic pain patients. Eur J Pain 16, 1414-1425.
130. Scholz, J., Woolf, C.J., (2007). The neuropathic pain triad: Neurons, immune cells and glia. Nat Neurosci 10, 1361-1368.
131. Scott, M.A., Letrent, K.J., Hager, K.L., Burch, J.L., (1999). Use of transdermal amitriptyline gel in a patient with chronic pain and depression. Pharmacotherapy 19, 236-239.
132. v1.8 expression is not restricted to nociceptors in mouse peripheral nervous system. Pain 153, 2017-2030.
133. Simpson, D.M., Brown, S., Tocias, J., (2008). Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 70, 2305-2313.
134. Simpson, D.M., Gazda, S., Brown, S., Webster, L.R., Lu, S.P., Tobias, J.K., Vanhove, G.F., (2010). Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage 39, 1053-1064.
135. Slatkin, N.E., Rhiner, M., (2003). Topical ketamine in the treatment of mucositis pain. Pain Med 4, 298-303.
136. Smith, B.H., Torrance, N., (2012). Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep 16, 191-198.
137. Smith, H.S., (2009). Pain-skin deep at times. Pain Physician 12, 919-921.
138. Sorensen, L., Molyneaus, L., Yue, D.K., (2006). The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diabetes Care 29, 883-887.
139. Sowa, N.A., Street, S.E., Vihko, P., Zylka, M.J., (2010a). Prostatic acid phosphatase reduces thermal sensitivity and chronic pain sensitization by depleting phosphatidylinositol 4,5-bisphosphate. J Neurosci 30, 10282-10293.
140. Sowa, N.A., Taylor-Blake, B., Zylka, M.J., (2010b).) Ecto-5′- nucleotidase (CD73) inhibits nociception by hydrolyzing AMP to adenosine in nociceptive circuits. Neuroscience 30, 2235-2244.
141. Stein, C., Clark, D.J., Oh, U., Vasko, M.R., Wilcox, G.L., Overland, A.C., Vanderah, T.W., Spencer, R.H., (2009). Peripheral mechanisms of pain and analgesia. Brain Res Rev 60, 90-113.
142. Strumper, D., Durieux, M.E., (2004). Antidepressants as long-acting analgesics. Reg Anesth Pain Med 29, 277-285.
143. Sullivan, M.J., Thorn, B., Haythornthwaite, J.A., Keefe, F., Martin, M., Bradley, L.A., Lefebvre, J.C., (2001). Theoretical perspectives on the relation between catastrophizing and pain. Clin J Pain 17, 52-64.
144. Szallasi, A., Cortright, D.N., Blum, C.A., Eid, S.R., (2007). The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nature Rev Drug Discov 6, 357-372.
145. Takano, T., Chen, X., Luo, F., Fujita, T., Ren, Z., Goldman, N., Zhao, Y., Markman, J.D., Nedergaard, M., (2012). Traditional acupuncture triggers a local increase in adenosine in humans. J Pain 13, 1215-1223.
146. Taylor-Blake, B., Zylka, M.J., (2010). Prostatic acid phosphatase is expressed in peptidergic and non-peptidergic nociceptive neurons of mice and rats. PLoS ONE 5, e8674.
147. Tölle, T.R., (2010). Challenges with current treatment of neuropathic pain. Eur J Pain Suppl 4, 161-165.
148. Treede, R.D., Jensen, T.S., Campbell, J.N., Cruccu, G., Dostrovsky, J.O., Griffin, J.W., Hansson, P., Hughes, R., Nurmikko, T., Serra, J., (2008). Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology 70, 1630-1635.
149. Ulugol, A., Karadag, H.C., Tamer, M., Firat, Z., Aslantas, A., Dokmeci, I., (2002). Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocin-induced diabetic rats. Neurosci Lett 328, 129-132.
150. Verdu, B., Decosterd, I., Buclin, T., Stoiefel, F., Berney, A., (2008). Antidepressants for the treatment of chronic pain. Drugs 68, 2611-2632.
151. von Hehn, C.A., Baron, R., Woolf, C.J., (2012). Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 73, 638-652.
152. Vorobeychik, Y., Gordin, V., Mao, J., Chen, L., (2011). Combination therapy for neuropathic pain. A review of current evidence. CNS Drugs 25, 1023-1034.
153. Walker, J.M., Hohmann, A.G., (2005). Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol 168, 509-554.
154. Warncke, T., Jorum, E., Stubhaug, A., (1997). Local treatment with the N-methyl-D-aspartate receptor antagonist ketamine, inhibit development of secondary hyperalgesia in man by a peripheral actions. Neurosci Lett 227, 1-4.
155. Wasner, G., Kleinert, A., Binder, A., Schattschneider, J., Baron, R., (2005). Postherpetic neuralgia: Topical lidocaine is effective in nociceptor-deprived skin. J Neurol 252, 677-686.
156. Webster, L.R., Nunez, M., Tark, M.D., Eunteman, E.D., Lu, B., Tobias, J.K., Vanhove, G., (2011a). Tolerability of NGX-4010, a capsaicin 8% dermal patch, following pretreatment with lidocaine 2.5%/prilocaine 2.5% cream in patients with post-herpetic neuralgia. BMC Anesthesiol 11, 25.
157. Webster, L.R., Peppin, J.F., Murphy, F.T., Lu, B., Tobias, J.K., Vanhove, G.F., (2011b). Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. Diabetes Res Clin Pract 93, 187-197.
158. Webster, L.R., Peppin, J.F., Murphy, F.T., Tobias, J.K., Vanhove, G.F., (2012). Tolerability of NGX-4010, a capsaicin 8% patch, in conjunction with three topical anesthetic formulations for the treatment of neuropathic pain. J Pain Res 5, 7-13.
159. Webster, L.R., Tark, M., Rauck, R., Tobias, J.K., Vanhove, G.F., (2010). Effect of duration of postherpetic neuralgia on efficacy analyses in a multicentre, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia. BMC Neurol 10, 92.
160. Wehrfritz, A., Namer, B., Ihmsen, H., Mueller, C., Filitz, J., Koppert, W., Leffler, A., (2011). Differential effects on sensory functions and measures of epidermal nerve fiber density after application of a lidocaine patch (5%) on healthy human skin. Eur J Pain 15, 907-912.
161. Wilder-Smith, E.P., Ong, W.-Y., Guo, Y., Chow, W.-L., (2007). Epidermal transient receptor potential vanilloid 1 in idiopathic small nerve fibre disease, diabetic neuropathy and healthy human subjects. Histopathology 51, 674-680.
162. Wolff, R.F., Bala, M.M., Westwood, M., Kessels, A.G., Kleijnen, J., (2011). 5% Lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN) a systematic review. Acta Neurol Scand 125, 295-309.
163. Wotherspoon, G., Fox, A., McIntyre, P., Colley, S., Bevan, S., Winter, J., (2005). Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135, 235-245.
164. Xiao, W.H., Bennett, G.J., (2008). C-fiber spontaneous discharge evoked by chronic inflammation is suppressed by a long-term infusion of lidocaine yielding nanogram per milliliter plasma levels. Pain 137, 18-28.
165. Yu, X.H., Cao, C.Q., Martino, G., Puma, C., Morinville, A., St-Onge, S., Lessard, E., Perkins, M.N., Laird, J.M., (2010). A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain. Pain 151, 337-344.
166. Zeigler, D., Lynch, S.A., Muir, J., Benjamin, J., Max, M.B., (1992). Transdermal clonidine versus placebo in painful diabetic neuropathy. Pain 48, 403-408.
167. Zell-Kanter, M., Toerne, T.S., Spiefel, K., Negrusz, A., (2000). Doxepin toxicity in a child following topical administration. Ann Pharmacother 34, 328-329.
168. Zhao, P., Barr, T.P., Hou, Q., Dib-Hajj, S.D., Black, J.A., Albrecht, P.J., Petersen, K., Eisenberg, E., Wymer, J.P., Rice, F.L., Waxman, S.G., (2008). Voltage-gated sodium channel expression in rat and human epidermal keratinocytes: Evidence for a role in pain. Pain 139, 90-105.
169. Zur, E., (2013). Topical treatment of neuropathic pain using compounded medications. Clin J Pain. doi: 10.1097/AJP.0b013e318285d1ba.
170. Zylka, M.J., (2011). Pain relieving prospects for adenosine receptors and ectonucleotidases. Trends Molec Med 17, 188-196.
171. Zylka, M.J., Sowa, N.A., Taylor-Blake, B., Twomey, M.A., Herrala, A., Voikar, V., Vinho, P., (2008). Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine. Neuron 60, 111-122.